Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2026)

Maze Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 19595000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 40.23% year-over-year to 19595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90394000.0 (down 315.65% YoY) and the FY2025 annual result came in at 103585000.0, down 345.53% from the prior year.
• Income from Continuing Operations retreated to 19595000.0 in Q1 2026 per MAZE's latest filing, from 7033000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 139056000.0 in Q2 2024 and troughed at 39622000.0 in Q4 2024.
• A 3-year average of 8467777.78 and a median of 27733000.0 in 2024 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 82.25% in 2025, down 124.22% in 2025.
• Over 3 years, Income from Continuing Operations stood at 39622000.0 in 2024, then soared by 82.25% to 7033000.0 in 2025, then slumped by 178.62% to 19595000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 19595000.0, 7033000.0, and 30087000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.